FY2017 EPS Estimates for Novo Nordisk A/S Boosted by Leerink Swann (NVO)
Novo Nordisk A/S (NYSE:NVO) – Equities research analysts at Leerink Swann raised their FY2017 earnings per share (EPS) estimates for Novo Nordisk A/S in a report issued on Monday. Leerink Swann analyst S. Fernandez now forecasts that the company will post earnings per share of $2.41 for the year, up from their previous forecast of $2.38. Leerink Swann also issued estimates for Novo Nordisk A/S’s FY2018 earnings at $2.49 EPS, FY2019 earnings at $2.60 EPS, FY2020 earnings at $2.87 EPS and FY2021 earnings at $3.11 EPS.
TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/24/fy2017-eps-estimates-for-novo-nordisk-as-boosted-by-leerink-swann-nvo.html.
Other research analysts have also recently issued reports about the stock. BidaskClub cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. Zacks Investment Research lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. Bank of America Corporation raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, September 6th. Finally, BNP Paribas lowered Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research note on Monday, September 25th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $55.00.
Novo Nordisk A/S (NYSE NVO) opened at 50.20 on Tuesday. Novo Nordisk A/S has a 52-week low of $30.89 and a 52-week high of $50.95. The company’s 50-day moving average is $48.85 and its 200-day moving average is $43.75. The company has a market capitalization of $124.51 billion, a price-to-earnings ratio of 20.19 and a beta of 0.61.
A number of large investors have recently made changes to their positions in the business. Fisher Asset Management LLC boosted its position in Novo Nordisk A/S by 3.7% in the third quarter. Fisher Asset Management LLC now owns 12,124,724 shares of the company’s stock worth $583,806,000 after purchasing an additional 433,727 shares during the last quarter. Folketrygdfondet lifted its position in shares of Novo Nordisk A/S by 13.2% during the 2nd quarter. Folketrygdfondet now owns 6,914,192 shares of the company’s stock valued at $296,550,000 after buying an additional 803,608 shares in the last quarter. State Street Corp lifted its position in shares of Novo Nordisk A/S by 64,406.4% during the 1st quarter. State Street Corp now owns 5,593,351 shares of the company’s stock valued at $191,740,000 after buying an additional 5,584,680 shares in the last quarter. Everett Harris & Co. CA lifted its position in shares of Novo Nordisk A/S by 0.3% during the 2nd quarter. Everett Harris & Co. CA now owns 3,120,155 shares of the company’s stock valued at $133,823,000 after buying an additional 10,610 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Novo Nordisk A/S by 0.5% during the 2nd quarter. Northern Trust Corp now owns 1,975,217 shares of the company’s stock valued at $84,717,000 after buying an additional 9,319 shares in the last quarter. 6.03% of the stock is currently owned by institutional investors and hedge funds.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.